Chimeric antigen receptor T (CAR) T-cell therapy has transformed the treatment of relapsed and refractory hematologic malignancies.1 However, this treatment carries notable toxicity risks, including cytokine release syndrome, neurologic complications, and infections,2,3 and potentially greater intensive health care use.1,4 Real-world data on health care use after hospital discharge from CAR T-cell infusion are lacking but are needed for risk-stratified disease management strategies.4 We examined rehospitalizations and emergency department (ED) visits during the first 12 months after hospitalization for CAR T-cell infusion among commercially insured patients.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Kenzik KM, Johnson PC, Bhatia R, Bhatia S. Assessment of Hospitalizations and Emergency Department Visits After Chimeric Antigen Receptor T-Cell Therapy Among Commercially Insured Patients. JAMA Oncol. 2022;8(7):1068–1070. doi:10.1001/jamaoncol.2022.1044
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.